Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …

Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of
pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with …

Purpose: To assess the response to pexidartinib treatment in six cohorts of adult patients
with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor …

Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor
with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto …

11502 Background: TGCT is a rare neoplasm of the joint/tendon sheath associated with
colony-stimulating factor 1 (CSF-1) overexpression. No approved systemic therapy is …

Background The objective of this study was to report on the long‐term effects of pexidartinib
on tenosynovial giant cell tumor (TGCT). Methods This was a pooled analysis …

Background Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm,
overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved …

Pexidartinib is the first approved medication in the USA for people with tenosynovial giant
cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at …

Pexidartinib is an orally administered small molecule tyrosine kinase inhibitor. Phase III
ENLIVEN study results provided clinical evidence for US FDA approval for treatment of adult …

Background Pexidartinib is approved in the US for tenosynovial giant cell tumors (TGCTs).
Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs …